171 related articles for article (PubMed ID: 37000118)
41. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis.
Drobni ZD; Zafar A; Zubiri L; Zlotoff DA; Alvi RM; Lee C; Hartmann S; Gilman HK; Villani AC; Nohria A; Groarke JD; Sullivan RJ; Reynolds KL; Zhang L; Neilan TG
J Am Heart Assoc; 2020 Dec; 9(23):e018306. PubMed ID: 33190570
[TBL] [Abstract][Full Text] [Related]
42. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy.
Cone EB; Haeuser L; Reese SW; Marchese M; Nguyen DD; Nabi J; Chou WH; Noldus J; McKay RR; Kilbridge KL; Trinh QD
PLoS One; 2022; 17(11):e0272022. PubMed ID: 36318537
[TBL] [Abstract][Full Text] [Related]
43. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
44. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.
Zatarain-Nicolás E; Martín P; Márquez Rodas I; Virizuela J; Martín García A; Mitroi C; Cosín Sales J; Barrios V; Sánchez-Cabo F; Ibañez B; de Castro Carpeño J; López Fernández T
Clin Transl Oncol; 2023 Nov; 25(11):3073-3085. PubMed ID: 37227656
[TBL] [Abstract][Full Text] [Related]
46. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.
Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L
Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658
[TBL] [Abstract][Full Text] [Related]
47. Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression.
Mohammad KO; Fanous H; Vakamudi S; Liu Y
Cardiooncology; 2023 Mar; 9(1):15. PubMed ID: 36941689
[TBL] [Abstract][Full Text] [Related]
48. Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study.
Faron A; Isaak A; Mesropyan N; Reinert M; Schwab K; Sirokay J; Sprinkart AM; Bauernfeind FG; Dabir D; Pieper CC; Heine A; Kuetting D; Attenberger U; Landsberg J; Luetkens JA
Radiology; 2021 Dec; 301(3):602-609. PubMed ID: 34581628
[TBL] [Abstract][Full Text] [Related]
49. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
[TBL] [Abstract][Full Text] [Related]
50. High neutrophil-to-lymphocyte ratio is associated with cancer therapy-related cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapy.
Haj-Yehia E; Mincu RI; Korste S; Lampe L; Margraf SM; Michel L; Mahabadi AA; Ferdinandy P; Rassaf T; Totzeck M
Clin Res Cardiol; 2024 Feb; 113(2):301-312. PubMed ID: 37955712
[TBL] [Abstract][Full Text] [Related]
51. A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
Moradi A; Kodali A; Okoye C; Klein DH; Mohamoud I; Olanisa OO; Parab P; Chaudhary P; Mukhtar S; Mohammed L
Cureus; 2023 Jul; 15(7):e42071. PubMed ID: 37602125
[TBL] [Abstract][Full Text] [Related]
52. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
53. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
55. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
56. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
[TBL] [Abstract][Full Text] [Related]
57. Myocarditis Induced by Immunotherapy in Metastatic Melanoma-Review of Literature and Current Guidelines.
Czarnecka AM; Kleibert M; Płachta I; Rogala P; Wągrodzki M; Leszek P; Rutkowski P
J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079112
[TBL] [Abstract][Full Text] [Related]
58. Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis.
Thakker RA; Lee MA; Albaeni A; Elbadawi A; Suthar KH; Perez C; Sonstein LK; Farr NM; Venkatesan R; Khalife W; Berbarie RF; Chatila KF
Cardiol Res; 2021 Oct; 12(5):270-278. PubMed ID: 34691324
[TBL] [Abstract][Full Text] [Related]
59. A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents.
Duarte T; Costa C; Gonçalves S; Raposo L; Ferreira A; Albuquerque C; Vau N; Caria R
Rev Port Cardiol; 2022 Dec; 41(12):1047-1051. PubMed ID: 36257498
[TBL] [Abstract][Full Text] [Related]
60. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
